These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19125671)

  • 1. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection.
    Peleg AY; Monga D; Pillai S; Mylonakis E; Moellering RC; Eliopoulos GM
    J Infect Dis; 2009 Feb; 199(4):532-6. PubMed ID: 19125671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.
    Lenhard JR; Brown T; Rybak MJ; Meaney CJ; Norgard NB; Bulman ZP; Brazeau DA; Gill SR; Tsuji BT
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1584-91. PubMed ID: 26711763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of daptomycin resistance on Staphylococcus aureus virulence.
    Cameron DR; Mortin LI; Rubio A; Mylonakis E; Moellering RC; Eliopoulos GM; Peleg AY
    Virulence; 2015; 6(2):127-31. PubMed ID: 25830650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VraR Binding to the Promoter Region of
    Dai Y; Chang W; Zhao C; Peng J; Xu L; Lu H; Zhou S; Ma X
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin-intermediate Staphylococcus aureus isolates are attenuated for virulence when compared with susceptible progenitors.
    Cameron DR; Lin YH; Trouillet-Assant S; Tafani V; Kostoulias X; Mouhtouris E; Skinner N; Visvanathan K; Baines SL; Howden B; Monk IR; Laurent F; Stinear TP; Howden BP; Peleg AY
    Clin Microbiol Infect; 2017 Oct; 23(10):767-773. PubMed ID: 28396035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany.
    Bierbaum G; Fuchs K; Lenz W; Szekat C; Sahl HG
    Eur J Clin Microbiol Infect Dis; 1999 Oct; 18(10):691-6. PubMed ID: 10584894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyketides from marine-derived Aspergillus welwitschiae inhibit Staphylococcus aureus virulence factors and potentiate vancomycin antibacterial activity in vivo.
    Loges LA; Silva DB; Paulino GVB; Landell MF; Macedo AJ
    Microb Pathog; 2020 Jun; 143():104066. PubMed ID: 32068159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.
    Rose WE; Rybak MJ; Tsuji BT; Kaatz GW; Sakoulas G
    J Antimicrob Chemother; 2007 Jun; 59(6):1190-3. PubMed ID: 17434881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human antimicrobial peptide, LL-37, induces non-inheritable reduced susceptibility to vancomycin in Staphylococcus aureus.
    Friberg C; Haaber JK; Vestergaard M; Fait A; Perrot V; Levin BR; Ingmer H
    Sci Rep; 2020 Aug; 10(1):13121. PubMed ID: 32753585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.
    Sakoulas G; Eliopoulos GM; Moellering RC; Wennersten C; Venkataraman L; Novick RP; Gold HS
    Antimicrob Agents Chemother; 2002 May; 46(5):1492-502. PubMed ID: 11959587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid detection of Staphylococcus aureus strains having reduced susceptibility to vancomycin using a chemiluminescence-based drug-susceptibility test.
    Tajima Y; Komatsu M; Ito T; Hiramatsu K
    J Microbiol Methods; 2007 Sep; 70(3):434-41. PubMed ID: 17655957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.
    Moise PA; North D; Steenbergen JN; Sakoulas G
    Lancet Infect Dis; 2009 Oct; 9(10):617-24. PubMed ID: 19778764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycopeptide resistance in Staphylococcus aureus: is it a real threat?
    Gemmell CG
    J Infect Chemother; 2004 Apr; 10(2):69-75. PubMed ID: 15160298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
    Ghahremani M; Jazani NH; Sharifi Y
    J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
    Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
    Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus.
    Tenover FC; Biddle JW; Lancaster MV
    Emerg Infect Dis; 2001; 7(2):327-32. PubMed ID: 11294734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.
    Singh NB; Yim J; Jahanbakhsh S; Sakoulas G; Rybak MJ
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):363-370. PubMed ID: 29807674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
    Cui L; Tominaga E; Neoh HM; Hiramatsu K
    Antimicrob Agents Chemother; 2006 Mar; 50(3):1079-82. PubMed ID: 16495273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function.
    Sakoulas G; Eliopoulos GM; Fowler VG; Moellering RC; Novick RP; Lucindo N; Yeaman MR; Bayer AS
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2687-92. PubMed ID: 15980337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of RNAIII in vancomycin-intermediate Staphylococcus aureus strains regardless of the presence of agr mutation.
    Park C; Shin NY; Byun JH; Shin HH; Kwon EY; Choi SM; Kim SH; Kwon JC; Park SH; Choi JH; Yoo JH; Yoo JI; Chung GT; Lee DG
    J Med Microbiol; 2012 Mar; 61(Pt 3):345-352. PubMed ID: 22016559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.